

Pipeline

	Asset	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Rights
Oncology							
Off-the-shelf	VB10.16	HPV16+ cervical cancer					1
	VB10.16	HPV16+ head and neck cancer					2
	Regeneron programs	Undisclosed					3
	Internal	Undisclosed					
Individualized	VB10.NEO	Melanoma, lung, bladder, renal, head and neck cancer; locally advanced and metastatic tumors					4
	VB10.NEO	Locally advanced and metastatic tumors					4
Infectious Disease							
	Regeneron programs	Undisclosed					3
Autoimmune							
	Internal	Undisclosed					

1. Wholly-owned by Nykode. Potentially registrational. Roche supplies atezolizumab; 2. Wholly-owned by Nykode. Merck (MSD) supplies pembrolizumab; 3. Collaboration with Regeneron; 4. Genentech has an exclusive license to VB10.NEO.